NO832671L - Polypetider og fremgangsmaate for deres fremstilling - Google Patents

Polypetider og fremgangsmaate for deres fremstilling

Info

Publication number: NO832671L
Authority: NO; Norway
Prior art keywords: peptide; phe; stated; peptides; arg
Prior art date: 1982-07-26

Application number

NO832671A

Other languages

English (en)

Norwegian (no)

Inventor

Jean Edouard Frederic Rivier

Wylie Walker Vale Jr

Original Assignee

Salk Inst For Biological Studi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-26

Filing date

1983-07-22

Publication date

1984-01-27

1983-07-22 Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi

1984-01-27 Publication of NO832671L publication Critical patent/NO832671L/no

Links

238000000034 method Methods 0.000 title description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 76
239000001257 hydrogen Substances 0.000 claims abstract description 9
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims abstract description 6
125000002252 acyl group Chemical group 0.000 claims abstract description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 4
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
102000006771 Gonadotropins Human genes 0.000 claims description 10
108010086677 Gonadotropins Proteins 0.000 claims description 10
239000002622 gonadotropin Substances 0.000 claims description 10
229940094892 gonadotropins Drugs 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 5
230000028327 secretion Effects 0.000 claims description 5
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 4
239000003433 contraceptive agent Substances 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
HQMLIDZJXVVKCW-UWTATZPHSA-N (2r)-2-aminopropanamide Chemical compound C[C@@H](N)C(N)=O HQMLIDZJXVVKCW-UWTATZPHSA-N 0.000 claims 1
125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 1
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 abstract description 31
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 25
-1 acrylyl Chemical group 0.000 description 25
125000006239 protecting group Chemical group 0.000 description 23
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 21
150000001413 amino acids Chemical class 0.000 description 19
229920005989 resin Polymers 0.000 description 19
239000011347 resin Substances 0.000 description 19
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
241000124008 Mammalia Species 0.000 description 16
102000009151 Luteinizing Hormone Human genes 0.000 description 13
108010073521 Luteinizing Hormone Proteins 0.000 description 13
229940040129 luteinizing hormone Drugs 0.000 description 13
238000012360 testing method Methods 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 10
230000016087 ovulation Effects 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 9
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 8
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
229940088597 hormone Drugs 0.000 description 8
239000005556 hormone Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 7
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
206010062767 Hypophysitis Diseases 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000460 chlorine Substances 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 6
210000003635 pituitary gland Anatomy 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000003042 antagnostic effect Effects 0.000 description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
230000037396 body weight Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 5
210000002149 gonad Anatomy 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
150000003431 steroids Chemical class 0.000 description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
239000002253 acid Substances 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
229960003604 testosterone Drugs 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
239000004471 Glycine Substances 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
229940124558 contraceptive agent Drugs 0.000 description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
210000003016 hypothalamus Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000004475 Arginine Substances 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000001158 estrous effect Effects 0.000 description 2
230000004720 fertilization Effects 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
230000001456 gonadotroph Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
238000004810 partition chromatography Methods 0.000 description 2
235000008729 phenylalanine Nutrition 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229960005190 phenylalanine Drugs 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000002028 premature Effects 0.000 description 2
235000013930 proline Nutrition 0.000 description 2
229960002429 proline Drugs 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
238000005406 washing Methods 0.000 description 2
WBIIPXYJAMICNU-AWEZNQCLSA-N (2s)-5-[amino-[(4-methylphenyl)sulfonylamino]methylidene]azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC1=CC=C(S(=O)(=O)NC(N)=NCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C=C1 WBIIPXYJAMICNU-AWEZNQCLSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
241000024188 Andala Species 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
238000005915 ammonolysis reaction Methods 0.000 description 1
230000003509 anti-fertility effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000006286 dichlorobenzyl group Chemical group 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
229960002743 glutamine Drugs 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
239000002474 gonadorelin antagonist Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
235000014705 isoleucine Nutrition 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000006109 methionine Nutrition 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940077150 progesterone and estrogen Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000027272 reproductive process Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical group C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
235000014393 valine Nutrition 0.000 description 1
229960004295 valine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO832671A 1982-07-26 1983-07-22 Polypetider og fremgangsmaate for deres fremstilling NO832671L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/402,117 US4444759A (en)	1982-07-26	1982-07-26	GnRH Antagonists II

Publications (1)

Publication Number	Publication Date
NO832671L true NO832671L (no)	1984-01-27

Family

ID=23590595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO832671A NO832671L (no)	1982-07-26	1983-07-22	Polypetider og fremgangsmaate for deres fremstilling

Country Status (21)

Country	Link
US (1)	US4444759A (de)
EP (1)	EP0100218B1 (de)
JP (1)	JPS5946253A (de)
KR (1)	KR900003096B1 (de)
AT (1)	ATE33252T1 (de)
AU (1)	AU558402B2 (de)
CA (1)	CA1263500A (de)
DD (1)	DD216923A5 (de)
DE (1)	DE3376115D1 (de)
DK (1)	DK328183A (de)
ES (1)	ES8505335A1 (de)
GR (1)	GR78886B (de)
HU (1)	HU191865B (de)
IE (1)	IE55580B1 (de)
IL (1)	IL69098A (de)
MX (1)	MX7312E (de)
NO (1)	NO832671L (de)
NZ (1)	NZ204692A (de)
PH (1)	PH18967A (de)
PT (1)	PT77067B (de)
ZA (1)	ZA834645B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4619914A (en) *	1983-03-10	1986-10-28	The Salk Institute For Biological Studies	GNRH antagonists IIIB
IL70888A0 (en) *	1983-03-10	1984-05-31	Salk Inst For Biological Studi	Gn rh antagonist peptides and pharmaceutical compositions containing them
EP0145032B1 (de) *	1983-08-16	1987-11-04	Akzo N.V.	LH/RH-Antagonisten
ZA846154B (en) *	1983-08-16	1985-03-27	Akzo Nv	Lh-rh antagonists
US4547370A (en) *	1983-11-29	1985-10-15	The Salk Institute For Biological Studies	GnRH Antagonists
US4569927A (en) *	1984-02-23	1986-02-11	The Salk Institute For Biological Studies	GnRH Antagonists IV
IL74827A (en) *	1984-05-21	1989-06-30	Salk Inst For Biological Studi	Peptides active as gnrh antagonists and pharmaceutical compositions containing them
US4652550A (en) *	1984-05-21	1987-03-24	The Salk Institute For Biological Studies	GnRH antagonists VII
US4647653A (en) *	1984-08-23	1987-03-03	Tulane Educational Fund	Therapeutic peptides
US4565804A (en) *	1984-09-07	1986-01-21	The Salk Institute For Biological Studies	GnRH Antagonists VI
US4866160A (en) *	1985-04-09	1989-09-12	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
ZA862570B (en) *	1985-04-09	1986-12-30	Univ Tulane	Therapeutic decapeptides
US4705778A (en) *	1985-10-22	1987-11-10	Sri International	Orally active LHRH analogs
DE3634435A1 (de) *	1986-10-09	1988-04-14	Hoechst Ag	Analoga von gonadoliberin mit verbesserter loeslichkeit, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
US4935491A (en) *	1987-08-24	1990-06-19	Board Of Regents, The University Of Texas System	Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5110904A (en) *	1989-08-07	1992-05-05	Abbott Laboratories	Lhrh analogs
US5300492A (en) *	1988-02-10	1994-04-05	Tap Pharmaceuticals	LHRH analogs
DE68928278T2 (de) *	1988-02-10	1998-03-12	Tap Pharmaceuticals Inc	Lhrh-analog
US6326467B1 (en) *	1989-02-23	2001-12-04	Colorado State University Research Foundation	Hormone-recombinant toxin compounds and methods for using same
US5786457A (en) *	1989-02-23	1998-07-28	Colorado State University Research Foundation	Hormone-nuclease compounds and method for regulating hormone related diseases
AU5186090A (en) *	1989-02-23	1990-09-26	Colorado State University Research Foundation	Gnrh analogs for destroying gonadotrophs
US5084443A (en) *	1989-12-04	1992-01-28	Biomeasure, Inc.	Promoting expression of acetylcholine receptors with lhrh antagonist
US5965695A (en) *	1990-05-15	1999-10-12	Chiron Corporation	Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
IE66205B1 (en) *	1990-06-14	1995-12-13	Paul A Bartlett	Polypeptide analogs
US5656727A (en) *	1992-09-15	1997-08-12	The Administrators Of The Tulane Educational Fund	Antagonists of LHRH
US5480969A (en) *	1992-09-15	1996-01-02	The Administrators Of The Tulane Educational Fund	Antagonists of LHRH
US20050277582A1 (en) *	1993-07-20	2005-12-15	Nett Torrance M	Method for inactivating gonadotrophs
US5502035A (en) *	1993-08-06	1996-03-26	Tap Holdings Inc.	N-terminus modified analogs of LHRH
US5506207A (en) *	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US6455499B1 (en)	1999-02-23	2002-09-24	Indiana University Foundation	Methods for treating disorders associated with LHRH activity
US6598784B2 (en) *	2000-12-20	2003-07-29	Meadwestvaco Packaging Syatens, Llc	Beverage carton with strap type carrying handle
EP3125952B1 (de)	2014-03-31	2024-06-19	Iotech International, Inc.	Stabile zusammensetzungen von nichtkomplexiertem jod und verwendungsverfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4261887A (en) *	1973-11-06	1981-04-14	The Salk Institute For Biological Studies	Peptide compositions
US4072668A (en) *	1973-11-06	1978-02-07	The Salk Institute For Biological Studies	LH-RH Analogs
DE2617646C2 (de) *	1976-04-22	1986-07-31	Hoechst Ag, 6230 Frankfurt	Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4215038A (en) *	1978-10-16	1980-07-29	The Salk Institute For Biological Studies	Peptides which inhibit gonadal function
US4307083A (en) *	1978-10-16	1981-12-22	The Salk Institute For Biological Studies	LRF Antagonists
GB2053229B (en) *	1979-06-13	1983-03-02	Schally Andrew Victor	Lh-rh antagonists
US4253997A (en) *	1979-12-17	1981-03-03	American Home Products Corporation	Anti-ovulatory decapeptides
US4292313A (en) *	1980-04-15	1981-09-29	The Salk Institute For Biological Studies	LRF Antagonists
ATE8988T1 (de) *	1980-06-02	1984-09-15	Andrew Victor Schally	Lh-rh antagonisten.
US4341767A (en) *	1980-10-06	1982-07-27	Syntex Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
AU9102582A (en) *	1981-12-10	1983-06-16	David Howard Coy	Lh-rh antagonists

1982
- 1982-07-26 US US06/402,117 patent/US4444759A/en not_active Expired - Fee Related
1983
- 1983-06-24 NZ NZ204692A patent/NZ204692A/en unknown
- 1983-06-24 ZA ZA834645A patent/ZA834645B/xx unknown
- 1983-06-28 IL IL69098A patent/IL69098A/xx unknown
- 1983-06-29 AU AU16371/83A patent/AU558402B2/en not_active Ceased
- 1983-07-06 IE IE1582/83A patent/IE55580B1/en unknown
- 1983-07-15 DK DK328183A patent/DK328183A/da not_active Application Discontinuation
- 1983-07-20 PT PT77067A patent/PT77067B/pt unknown
- 1983-07-21 GR GR71998A patent/GR78886B/el unknown
- 1983-07-22 NO NO832671A patent/NO832671L/no unknown
- 1983-07-22 EP EP83304265A patent/EP0100218B1/de not_active Expired
- 1983-07-22 DE DE8383304265T patent/DE3376115D1/de not_active Expired
- 1983-07-22 ES ES524370A patent/ES8505335A1/es not_active Expired
- 1983-07-22 AT AT83304265T patent/ATE33252T1/de not_active IP Right Cessation
- 1983-07-25 KR KR1019830003427A patent/KR900003096B1/ko not_active Expired
- 1983-07-25 HU HU832619A patent/HU191865B/hu not_active IP Right Cessation
- 1983-07-25 DD DD83253375A patent/DD216923A5/de not_active IP Right Cessation
- 1983-07-25 PH PH29280A patent/PH18967A/en unknown
- 1983-07-26 MX MX8310714U patent/MX7312E/es unknown
- 1983-07-26 JP JP58136693A patent/JPS5946253A/ja active Pending
- 1983-07-26 CA CA000433229A patent/CA1263500A/en not_active Expired

Also Published As

Publication number	Publication date
DE3376115D1 (en)	1988-05-05
IE55580B1 (en)	1990-11-07
JPS5946253A (ja)	1984-03-15
ATE33252T1 (de)	1988-04-15
NZ204692A (en)	1986-03-14
IL69098A0 (en)	1983-10-31
AU1637183A (en)	1984-02-02
DK328183A (da)	1984-01-27
PT77067B (en)	1986-01-27
GR78886B (de)	1984-10-02
ES524370A0 (es)	1985-05-16
KR900003096B1 (ko)	1990-05-07
KR840005710A (ko)	1984-11-15
CA1263500A (en)	1989-11-28
DD216923A5 (de)	1985-01-02
EP0100218B1 (de)	1988-03-30
PT77067A (en)	1983-08-01
HU191865B (en)	1987-04-28
IE831582L (en)	1984-01-26
US4444759A (en)	1984-04-24
DK328183D0 (da)	1983-07-15
EP0100218A2 (de)	1984-02-08
EP0100218A3 (en)	1984-08-15
PH18967A (en)	1985-11-26
ES8505335A1 (es)	1985-05-16
IL69098A (en)	1986-09-30
ZA834645B (en)	1984-03-28
AU558402B2 (en)	1987-01-29
MX7312E (es)	1988-05-11

Publication	Publication Date	Title
NO832671L (no)	1984-01-27	Polypetider og fremgangsmaate for deres fremstilling
CA1262399A (en)	1989-10-17	Gnrh antagonists
US4565804A (en)	1986-01-21	GnRH Antagonists VI
HU204849B (en)	1992-02-28	Process for producing gnrh-antagonist decapeptide derivatives
EP0162575B1 (de)	1991-09-04	GNRH-Antagonisten-VII
US4652550A (en)	1987-03-24	GnRH antagonists VII
EP0063423B1 (de)	1985-08-14	GnRH-Antagonisten
US4619914A (en)	1986-10-28	GNRH antagonists IIIB
US4740500A (en)	1988-04-26	GnRH antagonists VIII
NO840880L (no)	1984-09-11	Peptid og fremgangsmaate for dets fremstilling
EP0038135B1 (de)	1984-07-11	LRF-Antagonisten
IE58287B1 (en)	1993-08-25	Spiro-heteroazolones for treatment of diabetes complications
KR910002702B1 (ko)	1991-05-03	펩티드의 제법
JPS59186948A (ja)	1984-10-23	ＧｎＲＨ「きつ」抗物質
HU189504B (en)	1986-07-28	Process for preparing decapeptide derivatives inhibiting the release of luteinizing hormone